Prime Therapeutics

Eagan, Minnesota
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Caution
Medium Risk


Prime Therapeutics does not provide viewpoint protections for its employees but has not publicly canceled business relationships based on views or beliefs. The company covers transgender-related medical costs for its employees and their children. It also uses sex and gender ideology criteria in vendor selection and philanthropic support. Prime Therapeutics appears to prioritize diversity over merit in its business practices, including its hiring. The company "look[s] forward to taking additional steps to attract and hire diverse candidates". Prime Therapeutics signed the Health Sector Climate Pledge, committing itself to achieve net zero emissions by 2050. Signatories are expected to develop and release a climate resilience plan and appoint a corporate executive to oversee its implementation. Prime Therapeutics supports DEI in its business practices and claims to have"made progress in infusing [its] diversity, equity and inclusion (DEI) values into [its] business". The company’s CEO, Kenneth H. Paulus, signed the CEO Action for Diversity & Inclusion pledge, which includes a commitment to promote DEI through bias education training in the workplace. Prime Therapeutics has supported LGBT advocacy organizations such as Out Youth Austin and the Trevor Project. However, the company does not appear to discriminate against charitable organizations based on views or beliefs. Prime Therapeutics has not used its PAC donations for ideological purposes. For these reasons, Prime Therapeutics receives a Medium Risk rating.

View Full Corporate Bias Ratings Report
Generate Reports